A Pharmaceopidemiological Study in Patients Who Use Symbicort SMART

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00503061
Recruitment Status : Completed
First Posted : July 18, 2007
Last Update Posted : December 1, 2010
Information provided by:

Brief Summary:
To investigate how common it is that patients using Symibort SMART take high average daily doses that are not considered appropriate by their physician (overuse) or are hospitalised due to their asthma at least partly due to underuse.

Condition or disease
Bronchial Asthma

Study Type : Observational
Actual Enrollment : 1000 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Pharmaceopidemiological Study in Patients Who Use Symbicort Turbuhaler as Maintenance and Reliever Therapy (Symbicort SMART) Capturing Over Use and Under Use Via the General Practice Research Database
Study Start Date : June 2007
Actual Primary Completion Date : May 2010
Actual Study Completion Date : May 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Population comes from Primary Care Clinics and Pulmonary Experts

Inclusion Criteria:

  • Asthma diagnosis, patient registered with the prescribing physician for at least one year before the qualifying prescription of Symbicort, prescription of Symbicort SMART after UK launch of the concept

Exclusion Criteria:

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00503061

United Kingdom
Research Site
London, United Kingdom
Sponsors and Collaborators
Principal Investigator: Catriona McMahon, MD AZ UK MC
Study Director: Tomas Andersson, MD AZ R&D Lund

Additional Information:
Responsible Party: Tomas Andersson, MSD, AstraZeneca Pharmaceuticals Identifier: NCT00503061     History of Changes
Other Study ID Numbers: D5890C00017
First Posted: July 18, 2007    Key Record Dates
Last Update Posted: December 1, 2010
Last Verified: November 2010

Keywords provided by AstraZeneca:
Symbicort SMART

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Budesonide, Formoterol Fumarate Drug Combination
Anti-Asthmatic Agents
Respiratory System Agents